A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 335-341

  Hensley, Martee L ^a   Dizon, Don ^b   Derosa, Felicia ^a   Venkatraman, Ennapadam ^a   Sabbatini, Paul ^a   Chi, Dennis S ^a   Dupont, Jakob ^a   Colevas, A Dimitrios ^a   Spriggs, David ^a   Aghajanian, Carol ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Dose; Epothilone; Gemcitabine; Phase I study; Solid tumors

Indexed keywords

DIPHENHYDRAMINE; GEMCITABINE; IXABEPILONE; RANITIDINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MELANOMA; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS; TUMOR RECURRENCE; UTERUS SARCOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; SARCOMA; URINARY BLADDER NEOPLASMS; UTERINE NEOPLASMS; WATER-ELECTROLYTE IMBALANCE;

EID: 34250648886     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9035-x     Document Type: Article

References (21)

1. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H (1996) Epothilone A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot 49:560-563
2. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
3. Kowalski RJ, Giannakakou P, Hamel E (1997) Activity of the microtubule-stabilizing agents epothilones A and B with purified tubulin in cells resistant to paclitaxel (TAXOL). J Biol Chem 272:2534-2541
4. Mani S, Macapinlac M Jr, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D (2004) The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 15:553-558
5. Aghajanian C, Burris HA, Jones S, Spriggs DR, Cohen M, Peck R, Sabbatini P, Hensley M, Greco FA, Dupont J, O'Connor OA (2007) A phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced malignancies and lymphomas. J Clin Oncol doi: 10.1200/JCO.2006.08.7304
6. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED, Southwest Oncology Group (2005) Ixabepilone (Epothilone B Analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group Trial S0111. J Clin Oncol 23:8724-8729
7. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ (2005) Multi-institutional randomized phase II trial of the epothilone B analog Ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446
8. Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JLP (2006) A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24:515-520
9. Roche HH, Cure H, Bunnell C, Cognetti, Mauriac F, Perez E, Miller K, J Sparano J, Peck R, Yelle L (2003) A phase II study of epothilone analog BMS-247550 in patients with metastatic breast cancer (MBS) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22 (Abstract 69)
10. Thomas E, Tabernero J, Fornier M, Fumoleau P, Lluch A, Viens P, Vahdat L, Conte P, Peck R, Martin M (2003) A phase II study of the epothilone B Analog BMS-247550 in patients with taxane-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 22 (Abstract 30)
11. Thomas E, Perez A, Mukhopadhyay P, Lerzo G, Pivot X, Bosserman LD, Mullaney B, Vahdat L, Hortobagyi GN (2006) Phase II trial of ixabepilone in patients with metastatic breast cancer (MBS) who are resistant to an anthracycline, a taxane and capecitabine. Proc Am Soc Clin Oncol 24 (Abstract 660)
12. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824-2831
13. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706-1712
14. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: pre-clinical pharmacology and mechanisms of action. Semin Oncol 23(suppl 10):3-15
15. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty minute infusion and fixed dose rate in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate response to treatment in solid tumors: European Organization for Research and Treatment of Cancers, National Cancer Institute of the United States, and National Cancer Institute of Cancer. J Natl Cancer Inst 92:205-216
17. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, Griffin T, Lebwohl DE, Liebes L, Muggia F, Horwitz SB (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289-1298
18. Hao D, Hammond LA, deBono JS, Tolcher AW, Berg AE, Bass A, Mays TA, Smith LS, Drengler R, Rowinsky EK (2002) Continuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 21:103a (Abstract 411)
19. Bilgin T, Ozalp S, Yalcin OT, Zorlu G, Vardar MA, Ozerkan K (2003) Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur J Gynaecol Oncol 24:169-170
20. Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK (2004) An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 92:314-319
21. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2003) Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90:593-596